Skip to content
value.today
Cardiovascular Simulation, Inc. logo

Cardiovascular Simulation, Inc.

Total raised
$382 M
6 rounds on record
Latest round
$65 M
Jun 2019
First round on record
Apr 2010
Today
Went public
See the company page

Cardiovascular Simulation, Inc. is listed today as Heartflow, Inc.: market value, financials and filings are on its company page.

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cardiovascular Simulation, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2019$65 MNo. 6$50 to $250 million

Cardiovascular Simulation, Inc.: Raise no. 6, Jun 2019

Investors in this round

9 investors had bought by the notice of Jun 14, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Cardiovascular Simulation, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$65 M of $100 M offered; $35 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles A. Taylor · Executive Officer, Director
  • Dana Mead · Executive Officer, Director
  • H. Baird A. Radford, III · Executive Officer
  • Noemi C. Espinosa · Executive Officer
  • Casey A. Tansey · Director
  • Jeff C. Lightcap · Director
  • John A. Stevens · Director
  • Kent A. Walker · Director
  • Lonnie A. Smith · Director
  • William A. Weldon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by H. Baird Radford, III, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 14, 2019. Read the notice at the SEC.

equitySEC
Nov 2017$90 MNo. 5$50 to $250 million

Cardiovascular Simulation, Inc.: Raise no. 5, Nov 2017

Investors in this round

2 investors had bought by the notice of Dec 4, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Cardiovascular Simulation, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$90 M of $150 M offered; $60 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles A. Taylor · Executive Officer, Director
  • Christopher K. Zarins · Executive Officer, Director
  • H. Baird M. Radford, Iii · Executive Officer
  • John Stevens · Executive Officer, Director
  • Noemi C. Espinoza · Executive Officer
  • Barry M. Uphoff · Director
  • Casey K. Tansey · Director
  • Jeff M. Lightcap · Director
  • Kent M. Walker · Director
  • Lonnie M. Smith · Director
  • Philip M. Young · Director
  • Tom M. Hawes · Director
  • William M. Weldon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by H. Baird Radford, III, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 4, 2017. Read the notice at the SEC.

equitySEC
Jan 2015$100 MNo. 4$50 to $250 million

Cardiovascular Simulation, Inc.: Raise no. 4, Jan 2015

Investors in this round

25 investors had bought by the notice of May 20, 2016: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Cardiovascular Simulation, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$100 M of $111 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles A. Taylor · Executive Officer, Director
  • Christopher K. Zarins · Executive Officer, Director
  • H. Baird M. Radford, III · Executive Officer
  • John Stevens · Executive Officer, Director
  • Nicky Espinosa Hayes · Executive Officer
  • Barry M. Uphoff · Director
  • Casey K. Tansey · Director
  • Jeff M. Lightcap · Director
  • Kent Espinosa Walker · Director
  • Lonnie M. Smith · Director
  • Philip M. Young · Director
  • Tom M. Hawes · Director
  • William M. Weldon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by H. Baird Radford, III, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed May 20, 2016. Read the notice at the SEC.

equitySEC
Dec 2011$105 MNo. 3$50 to $250 million

Cardiovascular Simulation, Inc.: Raise no. 3, Dec 2011

Investors in this round

29 investors had bought by the notice of Feb 27, 2014: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Cardiovascular Simulation, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$105 M of $107 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Stevens · Executive Officer, Director
  • Barry A. Uphoff · Director
  • Casey Tansey · Director
  • Charles A. Taylor · Director
  • Christopher K. Zarins · Director
  • Jeff C. Lightcap · Director
  • Jesse K. Du Bey · Director
  • Lonnie C. Smith · Director
  • Philip M. Young · Director
  • Thomas C. Hawes · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Stevens, President. Source: SEC Form D and 2 amendments, newest notice filed Feb 27, 2014. Read the notice at the SEC.

equitySEC
Aug 2010$20 MNo. 2$10 to $50 million

Cardiovascular Simulation, Inc.: Raise no. 2, Aug 2010

Investors in this round

10 investors had bought by the notice of Feb 4, 2011: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Cardiovascular Simulation, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $21 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Stevens · Executive Officer, Director
  • Barry A. Uphoff · Director
  • Casey Tansey · Director
  • Charles A. Taylor · Director
  • Christopher K. Zarins · Director
  • Philip M. Young · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Stevens, President. Source: SEC Form D and 1 amendment, newest notice filed Feb 4, 2011. Read the notice at the SEC.

equitySEC
Apr 2010$2 MNo. 1Under $2 million

Cardiovascular Simulation, Inc.: Raise no. 1, Apr 2010

Investors in this round

3 investors had bought by the notice of Apr 19, 2010: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Cardiovascular Simulation, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Stevens · Executive Officer, Director
  • Charles A. Taylor · Director
  • Christopher K. Zarins, M.D. · Director
  • Robert Mitchell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Stevens, President. Source: SEC Form D, newest notice filed Apr 19, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cardiovascular Simulation, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2019).

    SEC Form D · Jun 2019

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jun 2019

That is all the official record says: Cardiovascular Simulation, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Cardiovascular Simulation, Inc. are on record.

Investors#

13 named in official filings. Open an investor to see everything it has backed.

Investors in Cardiovascular Simulation, Inc.
InvestorKindAmountRoundRoleSource
Bain Capital Life Sciences Fund III, L.P.Fund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Bain Capital Life Sciences III General Partner, LLCFund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Bain Capital Life Sciences Investors, LLCFund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2025)SEC Form 3
BCLS Fund III Investments GP, LLCFund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2025)SEC Form 3
BCLS Fund III Investments, LPFund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Hcpciv 1, LLCOthernot statednot statedHeld Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025)SEC Form 3
HealthCor Partners Fund II, L.P.Fund or asset managernot statednot statedHeld Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025)SEC Form 3
HealthCor Partners Fund LPFund or asset managernot statednot statedHeld Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025)SEC Form 3
HealthCor Partners GP, LLCFund or asset managernot statednot statedHeld Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025)SEC Form 3
HealthCor Partners II, L.P.Fund or asset managernot statednot statedHeld Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025)SEC Form 3
HealthCor Partners LPFund or asset managernot statednot statedHeld Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025)SEC Form 3
HealthCor Partners Management LPFund or asset managernot statednot statedHeld Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025)SEC Form 3
William C. WeldonPersonnot statednot statedHeld Series D, F and F-1 preferred stock, director (Form 3, 2025)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 29 investors.

Largest shareholders today

Institutions holding Heartflow, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cardiovascular Simulation, Inc.
NameRoleNamed in
Charles A. TaylorExecutive officerJun 2019
Dana MeadExecutive officerJun 2019
H. Baird A. Radford, IIIExecutive officerJun 2019
Noemi C. EspinosaExecutive officerJun 2019
Christopher K. ZarinsExecutive officerDec 2017
H. Baird M. Radford, IiiExecutive officerDec 2017
John StevensExecutive officerDec 2017
Noemi C. EspinozaExecutive officerDec 2017
H. Baird M. Radford, IIIExecutive officerMay 2016
Nicky Espinosa HayesExecutive officerMay 2016
Casey A. TanseyDirectorJun 2019
Charles A. TaylorDirectorJun 2019
Dana MeadDirectorJun 2019
Jeff C. LightcapDirectorJun 2019
John A. StevensDirectorJun 2019
Kent A. WalkerDirectorJun 2019
Lonnie A. SmithDirectorJun 2019
William A. WeldonDirectorJun 2019
Barry M. UphoffDirectorDec 2017
Casey K. TanseyDirectorDec 2017
Christopher K. ZarinsDirectorDec 2017
Jeff M. LightcapDirectorDec 2017
John StevensDirectorDec 2017
Kent M. WalkerDirectorDec 2017
Lonnie M. SmithDirectorDec 2017
Philip M. YoungDirectorDec 2017
Tom M. HawesDirectorDec 2017
William M. WeldonDirectorDec 2017
Kent Espinosa WalkerDirectorMay 2016
Barry A. UphoffDirectorFeb 2014
Casey TanseyDirectorFeb 2014
Jesse K. Du BeyDirectorFeb 2014
Lonnie C. SmithDirectorFeb 2014
Thomas C. HawesDirectorFeb 2014
Eran K. BroshyDirectorFeb 2012
Christopher K. Zarins, M.D.DirectorApr 2010
Robert MitchellDirectorApr 2010

Went public since 2024. Its SEC number is that of a company listed on a stock exchange.